Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2014

01.06.2014 | Hepatobiliary Tumors

Expressions of Hypoxia-Inducible Factor-1 and Epithelial Cell Adhesion Molecule are Linked with Aggressive Local Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy

verfasst von: Shinichiro Yamada, MD, Tohru Utsunomiya, MD, PhD, Yuji Morine, MD, PhD, Satoru Imura, MD, PhD, Tetsuya Ikemoto, MD, PhD, Yusue Arakawa, MD, PhD, Mami Kanamoto, MD, PhD, Shuichi Iwahashi, MD, PhD, Yu Saito, MD, PhD, Chie Takasu, MD, PhD, Daichi Ishikawa, MD, Mitsuo Shimada, MD, PhD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiofrequency ablation (RFA) is a widely used therapy for hepatocellular carcinoma (HCC). Several reports have demonstrated the aggressive local recurrence of HCC after RFA, suggesting that induction of further malignant transformation of HCC has occurred.

Methods

Eighty-eight (88) patients with HCC who underwent hepatic resection were included in this study. Hepatectomy was indicated for local recurrence of HCC after RFA (n = 10, RFA group) and for HCC without prior RFA (n = 78, non-RFA group). Clinicopathological data and the patient’s prognosis after hepatectomy were compared between the two groups. Expression levels of hypoxia-inducible factor-1 (HIF-1), epithelial cell adhesion molecule (EpCAM), CD44, and vascular endothelial growth factor messenger RNA (mRNA) in the tumor tissues were also examined.

Results

The RFA group showed higher frequency of portal vein invasion and less tumor differentiation compared with the non-RFA group (p < 0.05). Overall and disease-free survival rates in the RFA group were significantly worse than those in the non-RFA group (p < 0.05). HIF-1 and EpCAM mRNA expression levels in the RFA group were significantly higher than those in the non-RFA group (p < 0.05).

Conclusions

These results suggest that local HCC recurrence after RFA shows an aggressive tumor phenotype and poor prognosis through the enhanced expressions of HIF-1 and EpCAM in the residual HCC tumors after insufficient or sub-lethal treatment by RFA.
Literatur
1.
Zurück zum Zitat El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef
2.
Zurück zum Zitat Steven AC, Francesco I, Lee ME, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91.CrossRef Steven AC, Francesco I, Lee ME, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91.CrossRef
3.
5.
Zurück zum Zitat Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg. 1995;221:291–8.PubMedCentralPubMedCrossRef Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg. 1995;221:291–8.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119–26.PubMedCrossRef Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119–26.PubMedCrossRef
7.
Zurück zum Zitat Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999;353:1676–7.PubMedCrossRef Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999;353:1676–7.PubMedCrossRef
8.
Zurück zum Zitat Nicoli N, Casaril A, Marchiori L, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg. 2001;8:417–21.PubMedCrossRef Nicoli N, Casaril A, Marchiori L, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg. 2001;8:417–21.PubMedCrossRef
9.
Zurück zum Zitat Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRef Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRef
10.
Zurück zum Zitat Choi D, Lim HK, Rhim H, Kim YS, Yoo BC, Paik SW, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007; 4:2319–29.CrossRef Choi D, Lim HK, Rhim H, Kim YS, Yoo BC, Paik SW, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007; 4:2319–29.CrossRef
11.
Zurück zum Zitat Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20–25.PubMedCrossRef Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20–25.PubMedCrossRef
12.
Zurück zum Zitat Nicoli N, Casaril A, Hilal MA, Mangiante G, Marchiori L, Ciola M, et al. A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 2004;188:165–7.PubMedCrossRef Nicoli N, Casaril A, Hilal MA, Mangiante G, Marchiori L, Ciola M, et al. A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 2004;188:165–7.PubMedCrossRef
13.
Zurück zum Zitat Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology. 2003;50:2179–84.PubMed Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology. 2003;50:2179–84.PubMed
14.
Zurück zum Zitat Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol. 2003;8:332–5.PubMedCrossRef Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol. 2003;8:332–5.PubMedCrossRef
15.
Zurück zum Zitat Tajima H, Ohta T, Okamoto K, Nakanuma S, Hayashi H, Nakagawara H, et al. Radiofrequency ablation induces dedifferentiation of hepatocellular carcinoma. Oncol Lett. 2010;1:91–4.PubMedCentralPubMedCrossRef Tajima H, Ohta T, Okamoto K, Nakanuma S, Hayashi H, Nakagawara H, et al. Radiofrequency ablation induces dedifferentiation of hepatocellular carcinoma. Oncol Lett. 2010;1:91–4.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Kong J, Kong J, Pan B, Ke S, Dong S, Li X, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1a/VEGFA. PLoS One. 2012;7:e37266.PubMedCentralPubMedCrossRef Kong J, Kong J, Pan B, Ke S, Dong S, Li X, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1a/VEGFA. PLoS One. 2012;7:e37266.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res. 2012;72:5600–12.PubMedCentralPubMedCrossRef Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res. 2012;72:5600–12.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Iida H, Suzuki M, Goitsuka R, Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 2012;40:71–9.PubMed Iida H, Suzuki M, Goitsuka R, Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 2012;40:71–9.PubMed
19.
Zurück zum Zitat Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, et al. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract. 2011;207:505–13.PubMedCrossRef Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, et al. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract. 2011;207:505–13.PubMedCrossRef
20.
Zurück zum Zitat Phillips RJ, Helbig KJ, Van der Hoek KH, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependent manner. World J Gastroenterol. 2012;18:3389–99.PubMedCentralPubMedCrossRef Phillips RJ, Helbig KJ, Van der Hoek KH, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependent manner. World J Gastroenterol. 2012;18:3389–99.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Zeng Z, Ren J, O’Neil M, Zhao J, Bridges B, Cox J, et al. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer. 2012;12:584.PubMedCentralPubMedCrossRef Zeng Z, Ren J, O’Neil M, Zhao J, Bridges B, Cox J, et al. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer. 2012;12:584.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol. 2003;38:977–81.PubMedCrossRef Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol. 2003;38:977–81.PubMedCrossRef
23.
Zurück zum Zitat Ono K, Kokubu S, Hidaka H, Watanabe M, Nakazawa T, Saigenji K. Risk factors of delay in restoration of hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma (HCC). Hepatol Res. 2005;31:172–7.PubMedCrossRef Ono K, Kokubu S, Hidaka H, Watanabe M, Nakazawa T, Saigenji K. Risk factors of delay in restoration of hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma (HCC). Hepatol Res. 2005;31:172–7.PubMedCrossRef
24.
Zurück zum Zitat Obara K, Matsumoto N, Okamoto M. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116–23.PubMedCentralPubMedCrossRef Obara K, Matsumoto N, Okamoto M. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116–23.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Yang SD, Lee SC, Chang HC. Heat stress induces tyrosine phosphorylation/activation of kinase FA/GSK-3 alpha (a human carcinoma dedifferentiation modulator) in A431 cells. J Cell Biochem. 1997;66:16–26.PubMedCrossRef Yang SD, Lee SC, Chang HC. Heat stress induces tyrosine phosphorylation/activation of kinase FA/GSK-3 alpha (a human carcinoma dedifferentiation modulator) in A431 cells. J Cell Biochem. 1997;66:16–26.PubMedCrossRef
26.
Zurück zum Zitat Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metast Rev. 2007;26:319–31.CrossRef Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metast Rev. 2007;26:319–31.CrossRef
27.
Zurück zum Zitat Simon F, Bockhorn M, Praha C, Baba HA, Broelsch CE, Frilling A, et al. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg. 2010;395:395–405.PubMedCrossRef Simon F, Bockhorn M, Praha C, Baba HA, Broelsch CE, Frilling A, et al. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg. 2010;395:395–405.PubMedCrossRef
28.
Zurück zum Zitat Xie H, Song J, Liu K, Ji H, Shen H, Hu S, et al. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients’ prognosis and hepatitis B virus X protein. Digest Dis Sci. 2008;53:3225–33.PubMedCrossRef Xie H, Song J, Liu K, Ji H, Shen H, Hu S, et al. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients’ prognosis and hepatitis B virus X protein. Digest Dis Sci. 2008;53:3225–33.PubMedCrossRef
29.
Zurück zum Zitat Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer. 2009;9:418.PubMedCentralPubMedCrossRef Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer. 2009;9:418.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54:910–9.PubMedCrossRef Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54:910–9.PubMedCrossRef
31.
Zurück zum Zitat Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Surg. 2013;20:429–34.CrossRef Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Surg. 2013;20:429–34.CrossRef
Metadaten
Titel
Expressions of Hypoxia-Inducible Factor-1 and Epithelial Cell Adhesion Molecule are Linked with Aggressive Local Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy
verfasst von
Shinichiro Yamada, MD
Tohru Utsunomiya, MD, PhD
Yuji Morine, MD, PhD
Satoru Imura, MD, PhD
Tetsuya Ikemoto, MD, PhD
Yusue Arakawa, MD, PhD
Mami Kanamoto, MD, PhD
Shuichi Iwahashi, MD, PhD
Yu Saito, MD, PhD
Chie Takasu, MD, PhD
Daichi Ishikawa, MD
Mitsuo Shimada, MD, PhD
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3575-z

Weitere Artikel der Sonderheft 3/2014

Annals of Surgical Oncology 3/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.